Background: A better understanding of the histopathology and molecular biology of lung cancer might improve our capability to predict the outcome for any individual patient. The purpose of this study was to evaluate several histopathologic and molecular markers in order to assess their prognostic value in stage I non-small cell lung cancer. Materials and Methods: One hundred ten patients at the Kyungpook National University Hospital were enrolled in the study. Histopathologic factors and molecular markers were selected. Results: Univariate analysis showed that the T stage, differentiation, visceral pleural invasion, and survivin expression were significantly associated with recurrence. Multivariate analysis demonstrated that differentiation and survivin overexpression emerged as independent prognostic factors of recurrence. Conclusion: In resected stage I non-small cell lung cancer, poor differentiation and survivin overexpression have been identified as independent predictors of poor disease-free survival.
INTRODUCTION
Lung cancer is the most common cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases and pathologic stage I represents the fastest growing segment due to the use of low-dose computed tomography for screening. Despite the potential benefits of surgical resection, the 5-year survival rate is only 60% to 70% in stage I patients, predominantly as a result of the development of distant metastasis [1, 2] .
Variation in survival largely reflects the heterogeneity of tumor biology, with some tumors having more aggressive growth and greater metastatic potential than others; therefore, current tumor stage alone cannot exactly establish the prognosis for these patients. New prognostic factors must be identified to help clinicians better assess the probability of survival and to optimize therapeutic strategies for each individual patient with pathologic stage I lung cancer. Several studies have already demonstrated possible prognostic roles for several biological factors in NSCLC and have found helpful tools for identifying patients with a poor prognosis [3] [4] [5] [6] .
Among those factors, thyroid transcription factor 1 (TTF-1) Sukki Cho, et al − 102 − expression, especially in adenocarcinoma, was known to be a prognostic factor as well as a differential diagnostic factor between primary lung cancer and other adenocarcinoma [7] .
Nuclear survivin expression might be an independent biomarker for disease recurrence and survival for NSCLC [8] .
Epidermal growth factor receptor (EGFR) overexpression may predict shorter survival in patients with resected stage I-IIIA NSCLC, although this is under debate [9] . E-cadherin is known to play a role in tumor progression and distant metastasis; therefore, reduced E-cadherin expression could potentially affect tumor differentiation and prognosis [10, 11] . As a result, the stratification of patients without lymph node involvement, according to prognostic risk, might aid in selecting a group of high-risk patients who would benefit from adjuvant therapy.
The purpose of this study is to evaluate several histopathologic variables and a panel of molecular markers-TTF-1, survivin, EGFR, and E-cadherin expression-in order to assess their prognostic value and their combined effects on recurrence in patients with resected stage I NSCLC.
MATERIALS AND METHODS

1) Patient characteristics
Between January 2003 and December 2006, a total of 110 patients (84 male, 26 female) with resected stage I NSCLC including squamous cell carcinoma (SCC), adenocarcinoma (AC), and bronchioalveolar carcinoma (BAC) were enrolled in the study. All patients in the study underwent potentially curative surgery consisting of lobectomy including sleeve resection and bilobectomy (n=104), pneumonectomy (n=4), or segmentectomy (n=2) and complete mediastinal lymph node dissection. None of the patients had neoadjuvant therapy.
Patients who died within one month after surgery were excluded from the study to avoid the bias of perioperative mortality. The age of the patients ranged from 41 to 79 years & ≤7 cm, ＞7 cm) was also recorded.
3) Immunohistochemical methods
Briefly, tissues were deparaffinized in xylene and rehydrated in graded alcohols and water. SCC=squamous cell carcinoma; AC=adenocarcinoma; BAC= bronchioalveolar carcinoma.
positive and negative controls. The negative controls were prepared by omitting the primary antibodies and known positive controls were included in each run.
4) Evaluation of immunohistochemical data
TTF-1 staining was assessed by the intensity relative to the strong staining intensity of type II pneumocytes as: negative (absent staining, 0), low expression (weak staining intensity, 
5) Statistical analysis
The chi-square test and Fisher's exact test were used to analyze the association between histopathologic variables, molecular variables, and recurrence. The time to relapse was defined as the period ranging from the date of surgery to the date when relapse was diagnosed. The specific time to recurrence curves were plotted using the Kaplan-Meier method, whereas the log-rank test was used to assess the statistical significance of differences between groups. Multivariate analyses were performed using the Cox proportional hazards model to identify independent prognostic factors. The criterion for significance was p＜0.1. 2) Immunohistochemical staining ( Table 2) TTF-1 expression was detected in 34 (30.9%) patients.
RESULTS
1) Histopathology (
EGFR overexpression was found in 54 (49.1%) of the patients. E-cadherin was lost in 10 (9.1%) cases. Overexpression of survivin was observed in 38 (34.5%) patients.
Sukki Cho, et al According to the positive area: 0 (＜25%), 1 (≥25% & ＜50%), 2 (≥50% & ＜75%), and 3 (≥75%). 3) Association between histopathologic and molecular factors (Table 3) TTF-1 expression was significantly high in several factors such as AC (p=0.000) and visceral pleural invasion (p=0.032);
however, it was not significantly associated with differentiation (p=0.670). The EGFR overexpression was more frequent in patients with SCC (p=0.076). Loss of E-cadherin was correlated with larger tumor size (p=0.061) and survivin (p=0.006, no expression).
4) Recurrence
The disease free interval was determined as the interval variate analysis for the prognostic significance of each histopathologic factor and molecular marker in relation to the time to recurrence. The log rank test showed that the T stage, differentiation, visceral pleural invasion, and survivin expression were prognostic factors (Fig. 1) . By multivariate analysis using the Cox proportional hazards regression model, poor differentiation and survivin expression emerged as independent prognostic factors of recurrence (Table 6 ).
DISCUSSION
The prognosis for patients with NSCLC was highly variable and a better understanding of the biology of tumors should provide useful information for predicting clinical outcomes and for individualizing treatment. Because lung cancer is a heterogeneous disease resulting from the acquisition of multiple somatic mutations, the prognostic role of histopathologic and molecular markers is difficult to determine [12] . As a significant fraction of the patients at stage I experience disease recurrence and die after a curative resection, the differ- SCC=squamous cell carcinoma; AC=adenocarcinoma; BAC=bronchioalveolar carcinoma; TTF-1=thyroid transcription factor 1; EGFR= epidermal growth factor receptor. In this study, we have evaluated factors such as TTF-1 and surviving, which have not been extensively studied. TTF-1 is mainly expressed in the thyroid and lung during embryogenesis, and it plays a physiological role in their development and morphogenesis. Positive TTF-1 staining by immunohistochemistry has been described in 25% to 80% of primary adnenocarcinoma; however, the vast majority of squamous cell carcinoma of the lung lacks TTF-1 expression [7] . In our study, TTF-1 positivity was 8.7% in squamous cell carcinoma and 66.7% in adenocarcinoma. TTF-1 positive adenocarcinoma had significant relationships with the prevalence of female, nonsmoker, negative staining of p53, less frequent retinoblastoma protein loss, and preserved expression of p27 [18] . Yatabe et al. [19] demonstrated that TTF-1 was consistently expressed during development and this pattern was preserved in transformed cells and metastatic lymph node.
Expression was not affected by the differentiation state.
However, Anagnostou et al. [7] showed that patients with stage I adenocarcinoma with TTF-1 expression had a longer median overall survival than those without expression and revealed TTF1-expression as an independent lower risk factor for patients with stage I adenocarcinoma.
EGFR is a member of the receptor tyrosine kinase (TK) family, and TKs regulate signaling pathways that control critical cellular activities [20] . The clinical importance of EGFR has increased with the development of EGFR TK inhibitors (TKI). EGFR mutations were observed more frequently in women, never-smokers, and in adenocarcinoma, and EGFR TKIs were more effective in patients with EGFR mutations.
Suzuki et al. [21] compared mutation with expression and reported that EGFR overexpression was significantly higher in cases where EGFR mutation was positive rather than negative. In this study, EGFR overexpression was more common in squamous cell carcinoma, men, and ever-smokers, which is in contrast with the findings of EGFR mutation. Therefore, the exact mechanism remains unclear whether EGFR mutation is the major contributor to EGFR overexpression.
E-cadherin and catenins are components of the adherens junction protein, with crucial roles in maintaining intercellular junctions in epithelial cells; reduced E-cadherin expression could potentially affect tumor differentiation, metastasis, and prognosis [10, 11] . Although the number of patients who have demonstrated the loss of E-cadherin is small, it still represents a significant prognostic factor.
Survivin is a recently identified protein that functions as an inhibitor of apoptosis, suppressing programmed cell death and regulating cell division. The expression of survivin is undetectable or found at very low levels in normal tissues but at high levels in various malignancies and also embryonic and fetal tissues [22] . The overexpression of survivin may overcome apoptotic checkpoints and promote aberrant progression of the transformed cell through mitosis. A high level of survivin expression in malignancies is considered to be an important indicator of poor prognosis and associated with high tumor grade, tumor progression, and chemoresistance [23] . Survivin staining was detected in both the nucleus and the cytoplasm of NSCLC. However, it was shown that nuclear survivin, rather than cytoplasmic staining, was predictive of poor survival in patients with NSCLC and esophageal cancer. Shinohara et al. [8] showed patients who had nuclear staining for survivin had a significantly increased risk of disease recurrence and concluded that the nuclear presence of Sukki Cho, et al − 108 − survivin may be an independent biomarker for disease recurrence and overall survival in patients with resected stage I and II NSCLC. Atikcan et al. [24] evaluated the prognostic significance of both nuclear and cytoplasmic survivin expression in NSCLC and showed that cytoplasmic staining was found to be significantly increased in squamous cell carcinoma and that nuclear survivin expression might predict prognosis in NSCLC, whereas cytoplasmic survivin has no prognostic significance.
This study had limitations. First, immunohistochemical scoring is at best a semi-quantitative exercise for which no standard criteria have yet been proposed or adopted. The scoring methods that have been used include estimating the grade of staining intensity, the percentage of tumor cells stained, the cellular localization of the antigen, and systems that combined these parameters. Second, a more important confusion is the method of determining cut-offs for dichotomizing scores in log-rank tests. Cut-offs are often arbitrary and are sometimes selected to obtain the desired effect using the minimum p-value approach. Therefore, different antibodies and grading systems should also be taken into account; the counting of positive tumor cells and grading of staining intensity may be subject to interobserver variability, which should be evaluated.
CONCLUSION
In resected stage I non-small cell lung cancer, poor differentiation and survivin overexpression have been identified as independent predictors of poor disease-free survival.
